Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains

US11084876B2 · kind B2 · utility

Assignee

• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Peter Kufer · Munich, DE
• Dirk Nagorsen · Munich, DE
• Juergen Scheele · Munich, DE
• Gerhard Zugmaier · Munich, DE
• Matthias Klinger · Gilching, DE
• Patrick Hoffmann · Munich, DE
• Virginie Naegele · Munich, DE
• Elaine-Pashupati Dopfer · Munich, DE

Key dates

• Filing date: May 24, 2017
• Grant date: Aug 10, 2021
• Expiry date: May 24, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.